Author Profile

Jazz to Buy Actio Biosciences, Expanding Rare Epilepsy Portfolio
The deal will give the company a potential first-in-class oral drug for rare form epilepsy. read more
Sionna Cuts Cystic Fibrosis Program After Trial Fail
The experimental small molecule failed to meet the key activity endpoint in a phase 2a trial. read more
Takeda Wins FDA Approval for Novel Narcolepsy Drug
The oral orexin receptor 2 agonist treats the orexin deficiency that leads to NT1. read more
Tarsus Pays $450M for Alkeus, Picking Up Phase 3 Stargardt Disease Drug
If approved, gildeuretinol will be the first FDA-approved therapy for the inherited retinal disease. read more
Lilly Cancer Drug Secures Second FDA Breakthrough Designation
A phase 1/2 study showed promising results in treating patients with advanced solid tumors. read more
Pfizer Looks to Expand Oral Alopecia Drug to Vitiligo
Already approved in alopecia, once-daily Litfulo improved facial and body vitiligo. read more
Supernus, Indivior Merge to Form CNS-Focused Company
The new CNS powerhouse offers 11 marketed drugs and projects $2.2B in annual revenue. read more
FDA Approves Fixed-Dose Tylenol-Naproxen Combo
The approval marks the first and only OTC, fixed-dose combo of acetaminophen and naproxen sodium. read more
Bain Capital to Buy UK Vitamin Company Vitabiotics
Through the deal, Bain will gain access to certain international markets, particularly MENA and China. read more
FDA Approves Otsuka First-in-Class ADHD Capsule
Simtriyo is the first norepinephrine, dopamine and serotonin reuptake inhibitor to treat ADHD. read more
Takeda Psoriasis Drug Shows Phase 3 Success in Hard-to-Treat Areas
Zasocitinib was able to clear or almost clear scalp psoriasis in 75% of trial patients. read more
Agios Drops Oral Sickle Cell Drug After Lackluster Trial
The PK activator was not sufficiently different from others in its class to continue development. read more
GSK Axes Blockbuster-Hopeful Cough Drug
GSK picked up the experimental cough drug in 2023 when it paid $2 billion to acquire Bellus Health. read more
Natoli Engineering Acquires Scheu & Kniss
The strategic investment expands Natoli’s capabilities while ensuring uninterrupted service for customers worldwide. read more
Merck Wins First FDA Approval for Once-Daily Oral PCSK9 Inhibitor for Hypercholesterolemia
Lipfendra reduced LDL-C by more than 50%, including in patients with HeFH. read more
Lilly Strikes Potential $3.8B Psychedelics Deal to Buy AtaiBeckley
The deal gives Lilly a pipeline of rapid-acting neuroplastogens. read more
Root Cause Analysis of Tablet Manufacturing Issues
Many formulation challenges such as poor flow, segregation, capping and weak tablets can be traced to suboptimal micromeritics properties. read more
AstraZeneca to Pay up to $1.5B for Oral Lung Cancer Drug from Dizal
The tablets were granted accelerated approval in China and U.S. for locally advanced/metastatic NSCLC with EGFR exon20ins. read more
Elevar-Hengrui Liver Cancer Combo Gets Third FDA Rejection
The partners have received a third CRL for their rivoceranib-camrelizumab combo in hepatocellular carcinoma. read more
Merck KGaA Gets Breakthrough Therapy Tag for Oral Lupus Drug
The selective TLR 7/8 inhibitor could become the first approved therapy for cutaneous manifestations of lupus. read more

May/June 2026

2026 Annual Buyer’s Guide
View Issue

Subscribe to Tablets & Capsules

Get started here for your complimentary print or digital subscription

Get started here for your complimentary print or digital subscription
Sign up Now »

Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox!